Atai Life Sciences and Beckley Psytech have received FDA Breakthrough Therapy designation for their nasal spray BPL-003 (mebufotenin benzoate), targeting treatment-resistant depression in adults
#ATAI #ATAIStock #ATAINews #ATAIStockNews #ataiLifeSciences #ataiLifeSciencesLifeSciencesStock
$ATAI
atai Life Sciences shares rose nearly 15% on Tuesday after mid-stage trial results showed that its two-dose nasal spray treatment, BPL-003, led to rapid, significant, and long-lasting improvements in depression symptoms, with benefits lasting up to three months.
#ATAI #ATAIStock #AtaiLifeSciences
Atai Life Sciences shares dropped over 15% in after-hours trading after its portfolio company Recognify Life Sciences reported that its schizophrenia drug inidascamine failed to meet the primary endpoint in a Phase 2b trial.
#ATAI #ATAIStock #ATAINews #ATAIStockNews #AtaiLifeSciences
$ATAI
Atai Life Sciences shares rose after its psychedelic drug BPL-003, developed with Beckley Psytech, showed statistically significant reductions in depressive symptoms in a mid-stage trial for treatment-resistant depression (TRD).
#ATAI #ATAIStock #ATAINews #ATAIStockNews #AtaiLifeSciences
